Literature DB >> 30361743

[Multivisceral resection with and without HIPEC in cancer surgery].

P Horvath1, A Königsrainer2.   

Abstract

BACKGROUND: Multivisceral resections seem to be naturally associated with an elevated morbidity rate. Data regarding the impact of multivisceral resections on progression-free and overall survival are only available in insufficient quantities.
OBJECTIVE: Data on multivisceral resections in cancer surgery are presented exemplified by gastric cancer, colorectal cancer and peritoneal metastases, focusing on overall and progression-free survival as well as morbidity and mortality.
MATERIAL AND METHODS: A PubMed search was carried out including the following terms: multivisceral resection, peritoneal metastases, cytoreduction, morbidity, HIPEC (hyperthermic intraperitoneal chemotherapy)
RESULTS: Multivisceral resections should only be performed if an R0 status can be achieved for all tumor entities. Preoperative performance of an FDG-PET-CT scan (fluorodeoxyglucose positron emission tomography computed tomography scan) can help in the selection of appropriate patients. In gastric cancer, extensive lymphatic metastases are associated with a poor overall survival despite multivisceral resection. Recurrent rectal cancer shows elevated morbidity rates and also decreased overall survival rates. Maximum cytoreductive surgery can be conducted for peritoneal metastasized appendiceal neoplasms and colorectal cancer with acceptable morbidity and without an increased risk for reduced overall survival.
CONCLUSION: After adequate patient selection and exclusion of stage IV distant metastatic disease, multivisceral resections can be offered to patients with the goal of an R0 resection.

Entities:  

Keywords:  Colon cancer; En-bloc resection; Gastric cancer; Morbidity; Rectal cancer

Mesh:

Year:  2019        PMID: 30361743     DOI: 10.1007/s00104-018-0754-7

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  21 in total

1.  Outcome of total pelvic exenteration for locally recurrent rectal cancer.

Authors:  Hideyuki Ike; Hiroshi Shimada; Shigeo Ohki; Shigeki Yamaguchi; Yasushi Ichikawa; Shouichi Fujii
Journal:  Hepatogastroenterology       Date:  2003 May-Jun

2.  Combined resection of invaded organs in patients with T4 gastric carcinoma.

Authors:  H Saito; S Tsujitani; Y Maeda; K Fukuda; K Yamaguchi; M Ikeguchi; M Maeta; N Kaibara
Journal:  Gastric Cancer       Date:  2001       Impact factor: 7.370

3.  Multivisceral resection for colon cancer: analysis of prognostic factors.

Authors:  Manuel López-Cano; Maria José Mañas; Eduardo Hermosilla; Eloy Espín
Journal:  Dig Surg       Date:  2010-06-22       Impact factor: 2.588

4.  Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.

Authors:  Yaniv Berger; Samantha Aycart; John P Mandeli; Marina Heskel; Umut Sarpel; Daniel M Labow
Journal:  Surg Oncol       Date:  2015-06-23       Impact factor: 3.279

Review 5.  Multivisceral resection for gastric cancer: a systematic review.

Authors:  Savtaj S Brar; Rajini Seevaratnam; Roberta Cardoso; Lavanya Yohanathan; Calvin Law; Lucy Helyer; Natalie G Coburn
Journal:  Gastric Cancer       Date:  2011-07-23       Impact factor: 7.370

6.  En bloc urinary bladder resection for locally advanced colorectal cancer: a 17-year experience.

Authors:  Jimmy C M Li; Charing C N Chong; Simon S M Ng; Raymond Y C Yiu; Janet F Y Lee; Ka Lau Leung
Journal:  Int J Colorectal Dis       Date:  2011-04-28       Impact factor: 2.571

7.  Appropriate selection of patients for combined organ resection in cases of gastric carcinoma invading adjacent organs.

Authors:  Oh Jeong; Won Yong Choi; Young Kyu Park
Journal:  J Surg Oncol       Date:  2009-08-01       Impact factor: 3.454

Review 8.  Multivisceral resection in colorectal cancer: a systematic review.

Authors:  H M Mohan; M D Evans; J O Larkin; J Beynon; D C Winter
Journal:  Ann Surg Oncol       Date:  2013-05-11       Impact factor: 5.344

9.  Multivisceral resection does not affect morbidity and survival after cytoreductive surgery and chemoperfusion for carcinomatosis from colorectal cancer.

Authors:  Jan Franko; Niraj J Gusani; Matthew P Holtzman; Steven A Ahrendt; Heather L Jones; Herbert J Zeh; David L Bartlett
Journal:  Ann Surg Oncol       Date:  2008-08-19       Impact factor: 5.344

10.  Pelvic exenteration for clinical T4 rectal cancer: oncologic outcome in 93 patients at a single institution over a 30-year period.

Authors:  Seiji Ishiguro; Takayuki Akasu; Shin Fujita; Seiichiro Yamamoto; Miranda Kusters; Yoshihiro Moriya
Journal:  Surgery       Date:  2008-12-23       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.